NCT00980538View on ClinicalTrials.gov

TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

December 9, 2009

Primary Completion Date

November 25, 2020

Study Completion Date

January 1, 2032

Conditions
HIV InfectionsHIV-1
Interventions
DRUG

Etravirine

Participants will be dosed with etravirine by weight up to a maximum dose of 200 mg bid until switched to an etravirine-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.

Trial Locations (29)

Unknown

Los Angeles

Washington D.C.

New York

Philadelphia

Buenos Aires

Ciudad Autonoma de Buenos Aire

Belo Horizonte

Ribeirão Preto

Rio de Janeiro

Montreal

Lyon

Paris

Panama City

Rio Piedras

Bucharest

Bloemfontein

Boksburg

Cape Town

Dundee

Durban

George

Johannesburg

Newtown

Pretoria

Esplugues de Llobregat

Madrid

Seville

Bangkok

Khon Kaen

All Listed Sponsors
lead

Janssen Sciences Ireland UC

INDUSTRY

NCT00980538 - TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants | Biotech Hunter | Biotech Hunter